Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

A related commentary discusses the implications of these study findings suggesting that the results “point to the possible existence of a subset of patients who might benefit disproportionately from the use of second-line gefitinib if they could be identified.”